BioSpace News Archive

Dyadic International, Inc. announced that it has entered into a Memorandum of Understanding with Essential Drugs Company Limited, the state owned pharmaceutical company under the Ministry of Health and Family Welfare of Bangladesh to facilitate biopharmaceutical research, pre-clinical development, cGMP production, clinical trials, regulatory and other relevant areas of interest in Bangladesh.

Rgenta Therapeutics today announced the formation of a Repeat Expansion Diseases (REDs) Focused Scientific Advisory Board (REDs SAB).

Blue Earth Diagnostics today announced the commercial availability of POSLUMA® (flotufolastat F 18) in the United States. POSLUMA (formerly referred to as to as 18F-rhPSMA-7.3) is an optimized, high-affinity radiohybrid (rh) Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging agent.

Organicell Regenerative Medicine, Inc . is pleased to announce the appointment of Harry L. Leider, MD, MBA as its new Chief Executive Officer (CEO).

Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer in AI-driven precision cardiovascular medicine tests, today announces the nationwide launch of PrecisionCHD™.

Intrinsic Therapeutics, Inc. announced today that Cigna Healthcare has issued a positive coverage policy for the Barricaid® Bone-Anchored Annular Closure device.

DiaMedica Therapeutics Inc. today announced it has entered into definitive agreements to sell its common shares in a private placement with accredited investors.

Lumos Pharma, Inc. (NASDAQ:LUMO) is hosting today a virtual Key Opinion Leader (KOL) Webinar where Drs. Fernando Cassorla and Michael Tansey will highlight the encouraging new data and analysis on oral LUM-201 for idiopathic PGHD from the Phase 2 PK/PD OraGrowtH212 and dose-finding OraGrowtH210 Trials presented at the Endocrine Society (ENDO) Annual Meeting.

Amarin Corporation plc (NASDAQ:AMRN) and its commercialization partner Biologix FZco, today announced that the Kingdom of Saudi Arabia’s (KSA) Saudi Food and Drug Authority (SFDA) has approved a new indication and label expansion for VASCEPA® (icosapent ethyl) capsules.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today highlighted recent Alport syndrome natural history data presented at the 60th ERA (European Renal Association) Congress.